Afina
Commercial- Indications
- Alzheimer's disease, Cerebral Amyloid Angiopathy
Company intelligence / Profile preview
NeuroVision Imaging is developing and clinically validating proprietary diagnostic platforms for early detection of Alzheimer’s disease and related neurodegenerative disorders. Their Afina™ retinal imaging system uses AI to identify amyloid signatures in the retina, while their ultra-multiplex blood test measures multiple biomarkers associated with brain amyloid accumulation. These technologies are being validated in large-scale studies, including collaborations with academic consortia such as AIBL. The company aims to commercialize these tests as laboratory developed tests (LDTs) and eventually as IVDs[1][2][3][8].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NeuroVision Imaging.